Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I PK and safety study of LY3526318 in healthy Japanese males
jRCT2071220072Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3526318 (5 arms), sponsored by Eli Lilly and Company. Started Nov 2022; status: active, not recruiting.
02
Drugs
LY3526318
Beyond the preview
Go deeper on jRCT2071220072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220072.